UK medical cannabis patients with MS reported improved quality of life across multiple domains over six months
Among 141 MS patients prescribed cannabis-based products, significant improvements were seen in cognitive function, physical health, anxiety, sleep, and social functioning over six months.
Quick Facts
What This Study Found
At 6 months, significant improvements in MSQoL-54 subscales: cognitive function, mental health composite, physical health, role limitations, social and sexual function. Also improved: EQ-5D-5L, GAD-7, and sleep quality. 146 adverse events; most mild (33%) or moderate (51%).
Key Numbers
141 patients. Significant improvements at 6 months across cognitive, physical, emotional, social, sexual function (all p<0.050). 146 adverse events. Mild: 33%. Moderate: 51%.
How They Did This
Observational analysis of 141 MS patients from the UK Medical Cannabis Registry prescribed CBMPs for more than one month, assessed at 1, 3, and 6 months.
Why This Research Matters
This is the largest UK real-world dataset on medical cannabis for MS. The breadth of improvement across cognitive, physical, emotional, and social domains suggests CBMPs may address multiple MS symptoms simultaneously.
The Bigger Picture
MS treatment focuses on disease modification, but patients suffer daily from symptoms those therapies don't address. This data adds evidence that cannabis products can meaningfully improve symptom burden.
What This Study Doesn't Tell Us
No control group. Improvements may reflect placebo, regression to mean, or natural fluctuation. Self-reported. Selection bias.
Questions This Raises
- ?Would these improvements hold in an RCT?
- ?Which formulation produces the best MS outcomes?
Trust & Context
- Key Stat:
- UK MS patients showed significant improvements across multiple quality of life domains after six months on prescribed cannabis
- Evidence Grade:
- Registry data without control group but with multiple significant outcomes across validated instruments.
- Study Age:
- 2024 publication.
- Original Title:
- Clinical outcome analysis of patients with multiple sclerosis - Analysis from the UK Medical Cannabis Registry.
- Published In:
- Multiple sclerosis and related disorders, 87, 105665 (2024)
- Authors:
- Murphy, Matthew, Kaur, Varinder(2), Bui, Hanh Lan, Yang, Toby, Erridge, Simon, Holvey, Carl, Coomber, Ross, Rucker, James J, Weatherall, Mark W, Sodergren, Mikael H
- Database ID:
- RTHC-05577
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Does medical cannabis help MS symptoms?
In this registry, 141 patients reported significant improvements in cognition, physical health, anxiety, sleep, and social functioning over six months. Without a control group, some improvement may reflect placebo.
Is it safe for MS patients?
146 adverse events across 141 patients, mostly mild or moderate. No serious safety signals over six months.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05577APA
Murphy, Matthew; Kaur, Varinder; Bui, Hanh Lan; Yang, Toby; Erridge, Simon; Holvey, Carl; Coomber, Ross; Rucker, James J; Weatherall, Mark W; Sodergren, Mikael H. (2024). Clinical outcome analysis of patients with multiple sclerosis - Analysis from the UK Medical Cannabis Registry.. Multiple sclerosis and related disorders, 87, 105665. https://doi.org/10.1016/j.msard.2024.105665
MLA
Murphy, Matthew, et al. "Clinical outcome analysis of patients with multiple sclerosis - Analysis from the UK Medical Cannabis Registry.." Multiple sclerosis and related disorders, 2024. https://doi.org/10.1016/j.msard.2024.105665
RethinkTHC
RethinkTHC Research Database. "Clinical outcome analysis of patients with multiple sclerosi..." RTHC-05577. Retrieved from https://rethinkthc.com/research/murphy-2024-clinical-outcome-analysis-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.